Bioventus (BVS) Gains from Investment Securities (2021 - 2024)

Bioventus (BVS) has 4 years of Gains from Investment Securities data on file, last reported at $345000.0 in Q4 2024.

• Quarterly Gains from Investment Securities rose 18.97% year-over-year to $345000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $345000.0 (down 74.78% YoY) and the FY2024 annual result came in at $1.4 million, up 97.91% from the prior year.
• Gains from Investment Securities fell to $345000.0 in Q4 2024, from $483000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $651000.0 in Q4 2021 to a low of -$463000.0 in Q4 2021.
• A 4-year average of $271533.3 and a median of $287000.0 in 2023 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 135.25% — and 2024, when it surged 592.86%.
• Tracing BVS's Gains from Investment Securities over 4 years: stood at -$463000.0 in 2021, then jumped by 160.91% to $282000.0 in 2022, then grew by 2.84% to $290000.0 in 2023, then climbed by 18.97% to $345000.0 in 2024.
• The last three Gains from Investment Securities figures came in at $345000.0 (Q4 2024), $483000.0 (Q3 2024), and $300000.0 (Q2 2024), per Business Quant data.